tetano
Editor, Senior Moderator
Curr Infect Dis Rep. 2012 Jan 18. [Epub ahead of print]
Influenza Virus Resistance to Neuraminidase Inhibitors: Implications for Treatment.
Shankaran S, Bearman GM.
Source
Hunter Holmes McGuire VA Medical Center, 1201 Broad rock Boulevard, Richmond, VA, 23249, USA, shivanjali.shankaran@gmail.com.
Abstract
Oseltamivir and Zanamivir are the two main Neuraminidase inhibitors used for the treatment of Influenza. Oseltamivir resistance has been identified in non-pandemic influenza viruses, as well as H1N1 pandemic Influenza A viruses. Resistance is associated with increased morbidity, and poorer outcomes in severely immunocompromised hosts. Newer neuraminidase inhibitors, increased vaccination and combination therapy may be alternatives for the treatment of Influenza in this setting.
PMID:
22249425
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22249425
Influenza Virus Resistance to Neuraminidase Inhibitors: Implications for Treatment.
Shankaran S, Bearman GM.
Source
Hunter Holmes McGuire VA Medical Center, 1201 Broad rock Boulevard, Richmond, VA, 23249, USA, shivanjali.shankaran@gmail.com.
Abstract
Oseltamivir and Zanamivir are the two main Neuraminidase inhibitors used for the treatment of Influenza. Oseltamivir resistance has been identified in non-pandemic influenza viruses, as well as H1N1 pandemic Influenza A viruses. Resistance is associated with increased morbidity, and poorer outcomes in severely immunocompromised hosts. Newer neuraminidase inhibitors, increased vaccination and combination therapy may be alternatives for the treatment of Influenza in this setting.
PMID:
22249425
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22249425